Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Preferred Stock Liabilities: 2012-2023

Historic Preferred Stock Liabilities for Gyre Therapeutics (GYRE) over the last 5 years, with Dec 2023 value amounting to $64.5 million.

  • Gyre Therapeutics' Preferred Stock Liabilities rose 93.72% to $64.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $64.5 million, marking a year-over-year increase of 93.72%. This contributed to the annual value of $64.5 million for FY2023, which is 93.72% up from last year.
  • As of FY2023, Gyre Therapeutics' Preferred Stock Liabilities stood at $64.5 million, which was up 93.72% from $33.3 million recorded in FY2022.
  • In the past 5 years, Gyre Therapeutics' Preferred Stock Liabilities registered a high of $64.5 million during FY2023, and its lowest value of $33.3 million during FY2022.
  • Moreover, its 2-year median value for Preferred Stock Liabilities was $48.9 million (2022), whereas its average is $48.9 million.
  • Data for Gyre Therapeutics' Preferred Stock Liabilities shows a peak YoY soared of 93.72% (in 2023) over the last 5 years.
  • Gyre Therapeutics' Preferred Stock Liabilities (Yearly) stood at $33.3 million in 2022, then spiked by 93.72% to $64.5 million in 2023.